| Typicality: | 0.423 |
| Saliency: | 0.405 |
| as ipilimumab | 5 | other |
| recently | 4 | temporal |
| in december | 4 | temporal |
| therapy → be approved by → the fda | 24 |
| therapy → be approved by → the food and drug administration | 6 |
| negative | neutral | positive |
| 0.061 | 0.535 | 0.404 |
| Raw frequency | 30 |
| Normalized frequency | 0.405 |
| Modifier score | 0.500 |
| Perplexity | 28.972 |